Cresco Labs Announces Record Revenue of $153.3 Million, Growth of $59 Million or 63% QoQ, and Adjusted EBITDA1 of $46.4 Million


Ryan Allway

November 23rd, 2020

News


Company affirms position as the largest wholesaler of branded products in the industry with $90.5 million in wholesale revenue

  • Record revenue of $153.3 million, 63% growth QoQ, an absolute increase of $59 million
  • Record adjusted EBITDA1 of $46.4 million, 182% growth QoQ
  • Record cashflow from operations of $17.8 million
  • Retail revenue growth of 60% QoQ to $62.8 million
  • Third consecutive quarter with over 40% revenue growth

CHICAGO–(BUSINESS WIRE)–Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), one of the largest vertically integrated multi-state cannabis operators in the United States, today released its unaudited financial results for the third quarter ended September 30, 2020. All financial information presented in this release is in U.S. dollars, unless otherwise noted.

Management Commentary

“Cresco Labs entered the third quarter firing on all cylinders achieving record levels of revenue, profitability, and cash flow. We remain the number one operator in the industry focused on, and delivering results in, the wholesale distribution of branded products. Our retail is outperforming, and we are generating substantial operating leverage,” said Charles Bachtell, Co-founder and CEO of Cresco Labs. “Comparing Q1 to Q3, we increased revenue by $87 million while keeping SG&A flat. The investments we made to support growth are paying off, and as a result our profitability has grown dollar for dollar with gross profit. Because of the decisions we’ve made, the changes we’ve managed through and the hard work devoted by our team over the last 12 months, Cresco Labs has substantiated itself within the very top tier of the industry and confirmed the value that is driven by our differentiated strategy. This is a unique story of strategic breadth, depth and execution. As we look toward our next phase of growth, it’s rinse and repeat – the playbook will be applied to more states and, again, we will achieve meaningful, material market positions.”

Third Quarter 2020 Financial Highlights

Operating Results

  • Revenue for the third quarter of 2020 was $153.3 million, an absolute increase of over $59.0 million or a 63% increase over Q2’20 revenue. Wholesale growth was driven by an increase in harvests from expanded capacity in Illinois and Pennsylvania with strong growth in California. Retail growth was driven by strong sequential same-store growth and two new store openings in Illinois.
  • Operational Gross Profit1 as a Percentage of Revenue was 53% in the quarter as compared to 47% in the prior quarter driven by increased efficiency in our expanded Illinois and Pennsylvania facilities.
  • Adjusted EBITDA1 was $46.4 million, an increase of 182% sequentially driven primarily from higher revenue, increased operational gross profit across our largest markets and strong SG&A control which dropped dramatically as a percentage of revenue.
  • Net Income2 was $4.9 million, which includes unrealized gains and losses on mark-to-market instruments that fluctuate until obligations are settled, changes in fair value of biological assets, interest expense and tax expense.
  • Net Cash Provided by Operating Activities was $17.8 million, compared to $9.9 million used in Q2. The increase in cash provided by operating activities was driven by increased operating leverage across the business as the Company scales.

Shares Outstanding

Total shares on a fully converted basis were 380,035,735 as of September 30, 2020.

Conference Call and Webcast

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Wednesday, November 18, 2020, at 8:30am Eastern Time (7:30am Central Time). The conference call may be accessed via webcast or by dialing 866-688-4235 (409-216-0711 for international callers) and providing conference ID 9237505. Archived access to the webcast will be available for one year on the Cresco Labs’ investor relations website.

Consolidated Financial Statements

The financial information reported in this press release is based on unaudited management prepared financial statements for the three months ended September 30, 2020. The Company expects to file its unaudited interim consolidated financial statements on SEDAR by November 18, 2020. All financial information contained in this press release is qualified in its entirety with reference to such financial statements. While the Company does not expect there to be any material changes between the information contained in this press release and the unaudited interim consolidated financial statements it files on SEDAR, to the extent that the financial information contained in this press release is inconsistent with the information contained in the Company’s financial statements, the financial information contained in this press release shall be deemed to be modified or superseded by the Company’s filed financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws. Further, the reader should refer to the additional disclosures in the Company’s audited financial statements for the year ended December 31, 2019, previously filed on SEDAR.

Cresco Labs references certain non-IFRS financial measures throughout this press release, which may not be comparable to similar measures presented by other issuers. Please see the “Non-IFRS Financial Measures” section at the end of this press release for more detailed information.

About Cresco Labs Inc.

Cresco Labs is one of the largest vertically-integrated multi-state cannabis operators in the United States. Cresco Labs is built to become the most important company in the cannabis industry by combining the most strategic geographic footprint with one of the leading distribution platforms in North America. Employing a consumer-packaged goods (“CPG”) approach to cannabis, Cresco Labs’ house of brands is designed to meet the needs of all consumer segments and includes some of the most recognized and trusted national brands including Cresco, Remedi and Mindy’s, a line of edibles created by James Beard Award-winning chef Mindy Segal. Sunnyside*, Cresco Labs’ national dispensary brand, is a wellness-focused retailer designed to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs has launched the industry’s first national comprehensive Social Equity and Educational Development (SEED) initiative designed to ensure that all members of society have the skills, knowledge and opportunity to work in and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.

Non-IFRS Financial Measures

Operational gross profit, EBITDA and Adjusted EBITDA, net of impact of biological assets, are non-IFRS measures and do not have standardized definitions under IFRS. The Company has provided these non-IFRS financial measures, which are not calculated or presented in accordance with IFRS, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. These supplemental non-IFRS financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believes that the supplemental non-IFRS financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-IFRS financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein. Accordingly, the Company has included below reconciliations of the supplemental non-IFRS financial measures to the most directly comparable financial measures calculated and presented in accordance with IFRS.

Forward Looking Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form dated April 28, 2020, and other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.

1 See “Non-IFRS Financial Measures” at the end of this press release for more information regarding the Company’s use of non-IFRS financial measures. Adjusted EBITDA is presented net of impact of biological assets.

2 Net income includes amounts attributable to non-controlling interests.

Cresco Labs Inc.
Unaudited Financial Information and Non-IFRS Reconciliations
(All amounts expressed in thousands of U.S. Dollars)
Unaudited Consolidated Statements of Operations
For the Three Months Ended September 30, 2020, June 30, 2020 and September 30, 2019

For the Three Months Ended

($ in thousands)

9/30/2020

6/30/2020

9/30/2019

Revenue

$

153,298

$

94,256

$

36,207

Cost of sales – production costs

(74,148

)

(60,835

)

(23,369

)

Gross profit before fair value adjustments

79,150

33,421

12,838

Realized changes in fair value of inventory sold

(72,560

)

(41,774

)

(22,908

)

Unrealized gain on changes in fair value of biological assets

78,041

77,822

30,910

Gross profit

84,631

69,469

20,840

GP%

55.2

%

73.7

%

57.6

%

Expenses:
Selling, general and administrative

46,763

45,186

25,474

Depreciation and amortization

5,800

5,358

991

Total expenses

52,563

50,544

26,465

Gain (loss) from operations

32,068

18,925

(5,625

)

Other (expense) income:
Interest expense, net

(11,319

)

(9,597

)

(1,094

)

Other (expense) income, net

(2,983

)

(740

)

2,714

Income from investment in associate

(134

)

24

35

Total other expense (income), net

(14,436

)

(10,313

)

1,655

Income (loss) before income taxes

17,632

8,612

(3,970

)

Income tax expense

(12,690

)

(13,312

)

(4,624

)

Net income (loss) 1

$

4,942

$

(4,700

)

$

(8,594

)

1 Net income (loss) includes amounts attributable to non-controlling interests.
Cresco Labs Inc.
Summarized Consolidated Statements of Financial Position
As of September 30, 2020 and December 31, 2019
September 30, 2020 December 31, 2019
($ in thousands) (Unaudited) (Audited)
Cash and cash equivalents

$

57,689

$

49,102

Other current assets

199,405

110,236

Property and equipment, net

180,649

155,839

Intangible assets, net

195,953

94,206

Goodwill

451,632

137,719

Other non-current assets

121,321

69,452

Total assets

$

1,206,649

$

616,554

Total current liabilities

243,731

150,169

Total long-term liabilities

221,294

143,762

Total shareholders’ equity

741,624

322,623

Total liabilities and shareholders’ equity

$

1,206,649

$

616,554

Cresco Labs Inc.
Unaudited Revenue and Gross Profit Metrics
For the Three Months Ended, September 30, 2020, June 30, 2020 and September 30, 2019

For the Three Months Ended

($ in thousands)

9/30/2020

6/30/2020

9/30/2019

Revenue

$

153,298

$

94,256

$

36,207

Cost of sales – production costs1

(74,148

)

(60,835

)

(23,369

)

Realized changes in fair value of inventory sold

(72,560

)

(41,774

)

(22,908

)

Unrealized gain on changes in fair value of biological assets

78,041

77,822

30,910

Gross profit

$

84,631

$

69,469

$

20,840

Cultivation costs expensed under IAS 412

(3,934

)

3,951

2,075

Net impact of fair value of biological assets

(5,481

)

(36,048

)

(8,002

)

Expansion, relaunch and rebranding costs3

2,693

4,616

2,157

COVID-19 related expenses

846

1,887

Fair value markup for acquired inventory

1,843

331

Operational gross profit (Non-IFRS)

$

80,598

$

44,206

$

17,070

Operational GP%

52.6

%

46.9

%

47.1

%

1 Production (cultivation, manufacturing, and processing) costs related to products sold during the period.
2 Costs would be capitalized under IAS 2 and do not reflect cost of inventory sold in the period.
Costs related to non-recurring third-party product costs, start-up costs, and samples/discounts to expand footprint and relaunch in certain markets.
Cresco Labs Inc.
Unaudited Reconciliation of Net Income to Adjusted EBITDA
For the Three Months Ended, September 30, 2020, June 30, 2020 and September 30, 2019
For the Three Months Ended
($ in thousands)

9/30/2020

6/30/2020

9/30/2019

Net income (loss)1

$

4,942

$

(4,700

)

$

(8,594

)

Depreciation and amortization

10,831

9,626

3,287

Interest expense, net

11,319

9,597

1,094

Income tax expense

12,690

13,312

4,624

Earnings before interest, taxes, depreciation
and amortization (EBITDA) (Non-IFRS)

$

39,782

$

27,835

$

411

Expansion, relaunch and rebranding costs2

2,693

4,616

2,157

COVID-19 related expenses

956

2,648

Other expense (income), net

2,983

740

(2,714

)

(Loss) gain from investment in associate

134

(24

)

(35

)

Fair value markup for acquired inventory

1,843

331

Cultivation costs expensed under IAS 413

(3,934

)

3,951

2,075

Adjustments for acquisition and other non-core costs

4,424

5,205

4,709

Management incentive compensation (share-based)

3,033

7,207

4,487

Adjusted EBITDA (Non-IFRS)

$

51,914

$

52,509

$

11,090

Net impact of fair value of biological assets

(5,481

)

(36,048

)

(8,002

)

Adjusted EBITDA (non-IFRS), net of impact of biological assets

$

46,433

$

16,461

$

3,088

1 Net income (loss) includes amounts attributable to non-controlling interests.
Costs related to non-recurring third-party product costs, start-up costs, and samples/discounts to expand footprint and relaunch in certain markets.
3 Costs would be capitalized under IAS 2 and do not reflect cost of inventory sold in the period.
Cresco Labs Inc.
Unaudited Summarized Consolidated Statements of Cash Flows
For the Three Months Ended, September 30, 2020, June 30, 2020 and September 30, 2019
For the Three Months Ended
($ in thousands)

9/30/2020

6/30/2020

9/30/2019

Net provided by (used in) operating activities

$

17,770

$

(9,881

)

$

(6,160

)

Net cash (used in) provided by investing activities

(12,147

)

14,888

(33,556

)

Net cash (used in) provided by financing activities

(18,869

)

(2,227

)

52,774

Effect of foreign currency exchange rate changes on cash

(1,005

)

(288

)

Net (decrease) increase in cash and cash equivalents

(14,251

)

2,492

13,058

Cash and cash equivalents and restricted cash, beginning of period

73,868

71,376

68,694

Cash and cash equivalents and restricted cash, end of period

$

59,617

$

73,868

$

81,752

 

Contacts

Media
Jason Erkes, Cresco Labs
Chief Communications Officer
press@crescolabs.com
312-953-2767

Investors
Jake Graves, Cresco Labs
Investor Relations Senior Analyst
investors@crescolabs.com

For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading